CNS Pharmaceuticals Inc. (CNSP)
0.10
0.00 (0.30%)
At close: Jan 28, 2025, 3:01 PM
Income Statement (Annual)
Get detailed income statement breakdowns, uncovering revenue, expenses, and much more.
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost of Revenue | 4.13K | 11.76K | 13.07K | 11.10K | 1.96K | n/a | n/a |
| Gross Profit | -4.13K | -11.76K | -13.07K | -11.10K | -1.96K | n/a | n/a |
| Operating Income | -18.87M | -15.27M | -14.03M | -9.45M | -3.83M | -881.79K | -215.10K |
| Interest Income | 13.88K | 7.03 | 9.29 | 3.26 | 44.23 | n/a | 10.22K |
| Pretax Income | -18.85M | -15.27M | -14.04M | -9.46M | -3.88M | -7.39M | -219.36K |
| Net Income | -18.85M | -15.27M | -14.50M | -9.46M | -3.88M | -7.39M | -526.47K |
| Selling & General & Admin | 4.77M | 5.97M | 4.68M | 4.39M | 1.98M | 860.52K | 182.47K |
| Research & Development | 14.10M | 9.30M | 9.35M | 5.06M | 1.85M | 21.27K | 32.64K |
| Other Expenses | n/a | n/a | n/a | n/a | n/a | -6.46M | n/a |
| Operating Expenses | 18.87M | 15.27M | 14.03M | 9.45M | 3.83M | 881.79K | 215.10K |
| Interest Expense | n/a | 7.03K | 9.29K | 3.26K | 44.23K | 46.70K | n/a |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | -255.45K |
| Cost & Expenses | 18.87M | 15.27M | 14.03M | 9.45M | 3.83M | 881.79K | 215.10K |
| Income Tax | n/a | 7.03K | 9.29K | 3.26K | 42.28K | 46.70K | -516.25K |
| Shares Outstanding (Basic) | 75.00K | 27.23M | 17.00M | 11.00M | 10.97M | 10.97M | 10.97M |
| Shares Outstanding (Diluted) | 75.35K | 27.23M | 17.57M | 11.08M | 10.97M | 10.97M | 10.97M |
| EPS (Basic) | -251.35 | -560.83 | -852.66 | -859.81 | -353.57 | -674.07 | -48.01 |
| EPS (Diluted) | -250.19 | -560.83 | -825.04 | -853.68 | -353.57 | -674.07 | -48.01 |
| EBITDA | -18.86M | -15.26M | -14.47M | -9.44M | -3.83M | -6.46M | n/a |
| Depreciation & Amortization | 4.13K | 11.76K | 13.07K | 11.10K | 1.96K | 881.79K | 516.25K |